Orchard Therapeutics has revealed its US pricing plans for Lenmeldy, its gene therapy for metachromatic leukodystrophy (MLD), placing a $4.25 million price tag on the one-shot treatment.
Libmeldy (atidarsagene autotemcel) was approved by the European Commission to treat metachromatic leukodystrophy (MLD) in December 2020, and subsequently rejected for NHS use by NICE last July on ...
The review was based on a PubMed search (search terms: ‘spinal cord’ AND ‘leukoencephalopathy’ OR ‘leukodystrophy’; ‘spinal cord’ AND ‘vitamin ... roots and cauda equina could be found in ...